Psilocybin and Depression

UNLOCKING NEW POSSIBILITIES The OPTIMIZE Study. Join us for a fascinating discussion on the OPTIMIZE Study at Vail Health, a new clinical study exploring the effects of psilocybin on depression in a clinical setting. We invite you to join this important discussion with Dr. Charles Raison, Director of Vail Health Behavioral Health Innovation Center, and Meghan McMunn with lived experience, to gain insight into the study’s design, potential impact, and how to get involved when the study launches in Spring 2025.